Federal contract award
75N91024C00006
PHASE I THERAPEUTIC AWARD: A NOVEL ENGINEERED BACTERIAL ANTICANCER IMMUNOTHERAPY FOR MERKEL CELL CARCINOMA
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | SMALL BUSINESS SET ASIDE - TOTAL |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $355.0K |
| Current contract value | $355.0K |
| Potential contract value / ceiling | $355.0K |
| Start date | Feb 21, 2024 |
| Current end date | Feb 20, 2026 |
| Potential end date | Feb 20, 2026 |
| Latest award activity | Jan 6, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jan 6, 2025 | P00002 | $0 | PHASE I THERAPEUTIC AWARD: A NOVEL ENGINEERED BACTERIAL ANTICANCER IMMUNOTHERAPY FOR MERKEL CELL CARCINOMA |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.